Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR6013510

— · cohortA4

d3f9b298-4b19-5d60-9d53-fd2d849b54d7

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortA4
subtype
cohortA4

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.490
  • FATTY_ACID_METABOLISM+0.410
  • ADIPOGENESIS+0.400
  • GLYCOLYSIS+0.390
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.390
  • MYC_TARGETS_V1+0.350
  • MTORC1_SIGNALING+0.330
  • PROTEIN_SECRETION+0.330
  • PEROXISOME+0.320
  • UV_RESPONSE_UP+0.310

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.460
  • IL6_JAK_STAT3_SIGNALING-0.370
  • INFLAMMATORY_RESPONSE-0.360
  • KRAS_SIGNALING_UP-0.280
  • APICAL_SURFACE-0.250
  • TNFA_SIGNALING_VIA_NFKB-0.240
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.220
  • SPERMATOGENESIS-0.170
  • G2M_CHECKPOINT-0.160
  • IL2_STAT5_SIGNALING-0.160

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1ee24b470-4509-4687-a91e-6d2b967336b9
colon-landscapes@1
——0.819
2BS_G3RJTBZD
brain-umap@2
high-grade glioma—0.800
3AUR-AD9I-TTM3-A-1-1-R-A542-39
breast-umap@18
—C0.796
4X8d72a357.7b39.4a0d.82f3.c9d54dbc70b6
lung-landscapes@6
—cohortA20.796
5SRR1516101
bladder-landscape@3
——0.790
6ULC1452T_S57
lung-landscapes@6
—cohortA10.782
7SRR6013598
lung-landscapes@6
—cohortA40.781
8MNG1094
mng-umap@100
——0.768
9TCGA-AN-A0FK-01A-11R-A034-07
breast-umap@18
—B0.759
10A0DA6087-9D43-41F9-8569-9F9320E4A9E8
brain-umap@2
——0.755

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.490Remibrutinib— uncovered
FATTY_ACID_METABOLISM0.410Inavolisib— uncovered
ADIPOGENESIS0.400Inavolisib— uncovered
GLYCOLYSIS0.390Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.390Inavolisib— uncovered
MYC_TARGETS_V10.350Inavolisib— uncovered
MTORC1_SIGNALING0.330Inavolisib— uncovered
PROTEIN_SECRETION0.330Remibrutinib— uncovered
PEROXISOME0.320Idelalisib— uncovered
UV_RESPONSE_UP0.310Idelalisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.300Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.290Inavolisib— uncovered
DNA_REPAIR0.240Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.220Inavolisib— uncovered
HEME_METABOLISM0.190Temsirolimus— uncovered
WNT_BETA_CATENIN_SIGNALING0.190Inavolisib— uncovered
MYC_TARGETS_V20.180Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.170Remibrutinib— uncovered
TGF_BETA_SIGNALING0.170Inavolisib— uncovered